175250 — Icure Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- KR₩77bn
- KR₩98bn
- KR₩69bn
- 18
- 29
- 59
- 25
Annual income statement for Icure Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 90,144 | 64,283 | 59,367 | 56,806 | 69,207 |
| Cost of Revenue | |||||
| Gross Profit | 18,097 | -4,659 | -5,580 | 1,298 | 7,607 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 100,648 | 96,692 | 87,511 | 81,702 | 95,315 |
| Operating Profit | -10,504 | -32,409 | -28,144 | -24,895 | -26,108 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11,498 | -38,835 | -43,090 | -32,525 | -388 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12,150 | -38,384 | -42,549 | -32,299 | 24.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -12,614 | -38,167 | -41,766 | -31,420 | 1,049 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12,614 | -38,167 | -41,766 | -31,420 | 1,049 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -664 | -1,423 | -1,753 | -799 | -365 |
| Dividends per Share |